Sight Sciences (SGHT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Sight Sciences

NasdaqGS•Healthcare•Medical Devices

$8.10-0.25(-0.03%)Pre-market

Market Cap

$440.41M

P/S

5.3x

P/B

8.3x

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

How this company scores

WeakMetricSide Score: 49/100

Grade capped at D — Interest coverage below 1× (-5.4x) — earnings cannot cover interest. Strongest: Profitability (17/25); weakest: Cash & Earnings Quality (5/25).

Profitability17/25

Growth14/25

Balance Sheet & Red Flags13/25

Cash & Earnings Quality5/25

Strengths

Long cash runwayProfit converts from growthNet cash positionImproving margins

Grade capped at D

Interest coverage below 1× (-5.4x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 5.3x5y range 1.6x – 9.0x

Currently above its 18-quarter median.

P/B · 8.3x5y range 1.3x – 8.3x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $440.41M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $83.38M
Q. Revenue: $23.39M
TTM EBITDA: $-27.46M
TTM Op. Income: $-27.87M
Q. Op. Income: $-3.89M
TTM Net Income: $-29.76M
Q. Net Income: $-4.45M
EPS: $-0.08
Shares Out.: $54.51M

$83.38M in TTM revenue grew 9.3% YoY, reaching $23.39M last quarter. TTM EBITDA of $-27.46M and TTM operating income of $-27.87M show growth is flowing through to the bottom line. However, net income is negative at $29.76M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 3 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 91.4%
EBITDA Margin: -16.2%
Op. Margin: -16.6%
Net Margin: -19.0%

Op. margin of -16.6% is up 43.0% YoY — cost efficiency is improving. Net margin at -19.0% and gross margin of 91.4% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 72% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 5.3x
P/B Ratio: 8.3x

P/S of 5.3x and P/B of 8.3x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $104.87M
Cash: $79.75M
Long-Term Debt: $30.64M
Book Value: $52.89M
D/E Ratio: 0.6
Debt/EBITDA: N/A

With $104.87M in assets and $30.64M in long-term debt, D/E is 0.6and book value is $52.89M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 2% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-5.66M
TTM Free Cash Flow: $-23.33M
FCF Margin: -28.0%
FCF / Net Income: 0.8

TTM FCF of $-23.33M on $-5.66M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.